Q-omics provides the consensus-scored CDC42SE1 profile across patient tissues and cancer cell-line models. CDC42SE1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CDC42SE1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, CDC42SE1 RNA expression shows 20,125 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where CDC42SE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC42SE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC42SE1 survival associations across molecular data types. CDC42SE1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC42SE1 RNA expression–survival associations across cancer types. High CDC42SE1 expression shows unfavorable associations in ACC, UVM, KIRP, MESO, SCLC and LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CDC42SE1 RNA expression.
This table summarizes CDC42SE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CDC42SE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC42SE1 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, BLCA, BRCA and UCEC. The HNSC box plot shows higher CDC42SE1 RNA expression in tumor versus normal tissue (log2 FC = +0.890, t-test p < 0.001).
This table shows molecular features associated with CDC42SE1 in patient tissues and cancer cell lines. In patient samples, CDC42SE1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CDC42SE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
